Research Projects & Grants

For Profit Organization

  • A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy, safety, and tolerability of JNJ-27018966 in the treatment of patients with diarrhea-predominant irritable bowel syndrome, Role: Investigator, Furiex Pharmaceuticals, (07/2012 - 07/2013) Status: Completed